WHO ICTRP trial
A Clinical study of Trastuzumab Deruxtecan as first line Treatment for Non-Small…
CTRI/2022/02/040116 · Clinical Trials Registry India (CTRI) · Not Recruiting
Key facts
| Trial ID | CTRI/2022/02/040116 |
|---|---|
| Public title | A Clinical study of Trastuzumab Deruxtecan as first line Treatment for Non-Small Cell Lung Cancer |
| Scientific title | An Open-label, Randomized, Multicenter, Phase 3 Study to Assess the Efficacy and Safety of Trastuzumab Deruxtecan as First-line Treatment of Unresectable, Locally Advanced, or Metastatic NSCLC Harboring HER2 Exon 19 or 20 Mutations (DESTINY-Lung04) |
| Primary sponsor | AstraZeneca AB |
| Secondary sponsors | AstraZeneca Pharma India Limited |
| Registry | Clinical Trials Registry India (CTRI) |
| Recruitment status | Not Recruiting |
| Study type | Interventional |
| Phase | Phase 3 |
| Countries | Australia;Brazil;Bulgaria;Canada;China;Denmark;France;Germany;Hong Kong;India;Italy;Japan;Mexico;Netherlands;Poland;Republic of Korea;Spain;Sweden;Taiwan;Turkey;United States of America |
| Conditions | Health Condition 1: C349- Malignant neoplasm of unspecifiedpart of bronchus or lung |
| Interventions | Intervention1: Trastuzumab Deruxtecan (T-DXd): Trastuzumab Deruxtecan ((T-DXd) monotherapy by IV administration Q3W until RECIST 1.1 defined progression by investigator Control Intervention1: Cisplatin or carboplatin with pemetrexed and… |
| Registration date | Aug 2, 2022 |
| Target size | 264 |
| Secondary IDs | 2021-000634-33;D967SC00001 VERSION 1.0, Dated 08 JUL 2021;NCT05048797 |
| Registry page | ctri.nic.in |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: